Midwife Maven
Hormone Therapy and what the research actually is telling us - timing matters.
The Timing of Hormone Therapy: What the Research Actually Says
Hormone therapy has one of the most complicated reputations in medicine. Here is what the evidence actually shows, and why formulation and timing matter more than most conversations acknowledge.
How We Got Here: The WHI and Its Aftermath
In July 2002, the Women’s Health Initiative (WHI) stopped early after finding elevated risks of breast cancer, heart disease, stroke, and blood clots in women taking oral conjugated equine estrogen plus the synthetic progestin medroxyprogesterone acetate (MPA). Headlines reduced two decades of complexity to a single message: hormone therapy causes cancer and heart attacks. Within two years, use among postmenopausal women dropped by nearly half.
That drop had costs. Millions of women were denied effective treatment for symptoms that significantly affected their quality of life, and a generation of clinicians was trained to treat hormone use as inherently risky rather than as a clinical tool with specific indications, contraindications, formulation differences, and timing-dependent effects.
The research picture today looks substantially different from 2002, and it is more nuanced and more actionable than either the original headlines or reflexive reassurances sometimes offered now.
What the WHI Actually Studied
The WHI studied a specific population using a specific regimen. The average participant age was 63, meaning most women were more than a decade past menopause. The regimen was oral conjugated equine estrogen (CEE) combined with medroxyprogesterone acetate (MPA), taken in continuous combination. That is not what most clinicians today would prescribe to a woman in her early 50s with perimenopausal symptoms.
Critics, including reproductive endocrinologists and cardiologists who reviewed the data carefully, identified two fundamental design problems. First, studying older women with pre-existing subclinical atherosclerosis and applying those findings to younger women initiating therapy at menopause ignores vascular biology: estrogen does not protect an already-inflamed artery. It maintains healthy endothelium when initiated while that endothelium is still intact. Second, oral CEE plus synthetic MPA is not the same as transdermal 17-beta estradiol plus micronized progesterone. The molecules matter. The route of delivery matters. Conclusions about one cannot automatically apply to the others.
The Timing Hypothesis
When WHI investigators stratified their data by age and years since menopause, a different picture emerged. Women aged 50 to 59 who initiated hormone therapy showed meaningfully lower absolute risks of adverse events than women aged 70 to 79. Among women within 10 years of menopause onset, the cardiovascular signal that alarmed investigators in the older group was largely absent. A 2007 reanalysis published in JAMA explicitly named timing as a key variable in the cardiovascular risk profile of hormone therapy.
The Nurses’ Health Study found that women who initiated hormone therapy within four years of menopause had roughly a 30 to 35 percent lower risk of coronary heart disease compared to non-users. Women initiating more than ten years after menopause showed no benefit and some evidence of increased risk. Animal model research confirmed the biology: estrogen prevented new atherosclerotic lesions when administered early after menopause, but had no effect on already-established lesions.
What current guidelines say
NAMS (2022), the Endocrine Society, ACOG, and the American College of Cardiology all support hormone therapy for symptomatic women under age 60 or within 10 years of menopause onset, without significant contraindications. Cardiovascular prevention is not an indication. Recognized indications include symptom relief, genitourinary health, bone protection, and quality of life. The risk profile for appropriately selected women is described as favorable when using contemporary formulations and appropriate routes of administration.
Why Formulation and Route Matter
When estrogen is taken orally, it passes through the liver before reaching systemic circulation. This first-pass hepatic metabolism activates coagulation factors, raises triglycerides and inflammatory proteins, and produces changes in blood viscosity that do not occur with transdermal delivery. Transdermal estradiol bypasses this effect entirely, entering the bloodstream in a form pharmacologically closer to ovarian estradiol.
The consequences are measurable. Multiple large observational studies have found that oral estrogen approximately doubles VTE risk, while transdermal estradiol at standard doses carries no significantly elevated VTE risk. A landmark 2007 study published in Circulation found odds ratios for VTE of 4.2 for oral estrogen versus 0.9 (essentially neutral) for transdermal. This changes the clinical risk calculation entirely for women with any elevated thrombotic risk. Stroke risk shows a similar pattern: oral estrogen carries modestly elevated stroke risk; transdermal estradiol at doses of 50 micrograms or less has not shown significant stroke risk elevation, and is what NICE guidelines specifically recommend for women with stroke risk factors.
Progestogens: Not All Progesterone Is the Same
Women with an intact uterus who use estrogen also require a progestogen to protect the endometrium. For decades, the available U.S. option was synthetic progestins, including MPA. Micronized progesterone is chemically identical to the progesterone the body produces and has a substantially different metabolic and cardiovascular profile than synthetic progestins.
Multiple studies have found that transdermal estradiol plus micronized progesterone does not increase VTE risk, while combinations using synthetic progestins may add thrombotic risk. Research on breast cancer risk also shows differences: estrogen-only therapy after hysterectomy carries no increased risk and in some analyses shows modestly reduced risk, while combined regimens carry some increased risk that varies with progestogen type, duration, and timing of initiation.
Absolute versus relative risk: putting numbers in context
The 2002 WHI reporting used relative risk language without absolute risk context. The 26% higher relative risk of breast cancer in the combined CEE/MPA group translated to approximately 8 additional cases per 10,000 women per year, which meets the threshold typically used to define a rare adverse event. For women under 60 initiating contemporary transdermal formulations within 10 years of menopause, the absolute risk of adverse events is substantially lower than the figures generated from a study population averaging age 63 using older oral formulations.
What Hormone Therapy Does and Does Not Treat
Vasomotor symptoms (hot flashes and night sweats) remain the clearest and most robustly supported indication. Nothing treats them as effectively. Genitourinary syndrome of menopause, including vaginal dryness, urinary urgency, and changes in sexual function, is highly responsive to either systemic hormone therapy or low-dose local vaginal estrogen. Local vaginal estrogen is absorbed minimally into systemic circulation and is appropriate even for women who are not candidates for systemic therapy.
Bone protection is well established across formulations and routes. Sleep disruption, mood, cognitive clarity, and sexual function often improve with hormone therapy, though the evidence for each is variable and the degree of improvement individual.
What hormone therapy is not recommended for: primary prevention of cardiovascular disease, primary prevention of dementia, or treatment of established cardiovascular disease. The timing hypothesis suggests cardiovascular-neutral to modestly favorable effects when initiated in the appropriate window, but that does not make cardiovascular prevention an indication.
The Conversation That Actually Matters
The hormone therapy decision is not a single binary yes or no. It is a conversation about which estrogen, which progestogen if needed, which route of delivery, at what dose, initiated when relative to menopause. These variables produce meaningfully different risk profiles.
What I push back on firmly is the idea that hormone therapy is inherently dangerous for all women, derived from a study of older women using formulations that do not represent contemporary prescribing practice. Equally, I push back on the idea that it is risk-free or that formulation differences do not matter. The goal is the actual conversation, based on the actual evidence, with the actual woman in front of me.
Sources
1. Rossouw JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-1477.
2. Cho L, et al. Rethinking menopausal hormone therapy: for whom, what, when, and how long? Circulation. 2023;147(7):597-610.
3. Manson JE, Kaunitz AM. Menopause management: getting clinical care back on track. New England Journal of Medicine. 2016;374(9):803-806.
4. The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
5. Canonico M, et al. Hormone therapy and venous thromboembolism among postmenopausal women. Circulation. 2007;115(7):840-845.
6. Mueck AO. Postmenopausal hormone therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone. Climacteric. 2012;15(S1):11-17.
7. Estradiol and Micronized Progesterone narrative review. Journal of Clinical Medicine. 2025;14(20):7328.
8. Hodis HN, Mack WJ. Menopausal hormone replacement therapy and reduction of all-cause mortality and cardiovascular disease: it’s about time and timing. Cancer Journal. 2022;28(3):208-223.
9. Shufelt CL, et al. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events. Menopause. 2014;21(3):260-266.
10. Grodstein F, et al. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture. Epidemiology. 1996;7(4):369-376. [Nurses’ Health Study]
11. NICE Guideline NG23 (updated 2024). Menopause: Diagnosis and Management. National Institute for Health and Care Excellence.
12. Baik SH, et al. Use of menopausal hormone therapy beyond age 65 years and health implications. Menopause. 2024;31(5):363-371.
Past Midwife articles:
#fortheloveofthegame
 | A guest post by
|